

Questions and Answers (Q&As) on data protection and the secondary use of personal data for medicines development and public health purposes

Workshop on the application of the General Data Protection Regulation (GDPR) in the area of health and Secondary Use of Data for Medicines and Public Health Purposes, 29 September 2020



Orsolya Eotvos, Assistant Data Protection Officer, European Medicines Agency




Overview



- Background
- Project need
- Project objective
- Structure of the draft Q&As
- Drafting status of the Q&As
- Next steps





european medicines agency



Project Need

- Patients and HCPs, Research performing or supporting infrastructures, Medicines developers
- Union data protection legislation (GDPR)



• How to use personal data for secondary purposes



Medicines development and scientific research

Public health **Regulatory** authorities Union data protection legislation (GDPR, EUDPR)



• How to use personal data for secondary purposes



Evidence base for decision-making, safety monitory and policy making



3

Project Objective

Develop a set of Question & Answers (Q&As)

Clarify compliance with data protection legislation




Ensure rights and freedoms of patients and consumers

Facilitate the secondary use of health data for medicines and public health purposes



- Clarify the concept of secondary use of data within the GDPR/EUDPR
- Clarify the concept of scientific research within the GDPR/EUDPR
- Clarify the **specific rules** applicable to scientific research and secondary use, e.g. legal basis (consent or other), data erasure and retention period, transparency





5

5

Presentation title (to edit, click Insert > Header & Footer)

Classified as restricted by the European Medicines Agency



KEY PRINCIPLES

Scope of the Q&As

What are personal data?

What are special categories of personal data?

What does secondary use of data mean?

When does the GDPR/EUDPR apply to secondary use of data?

What are the data protection principles?

How long personal data can be retained?





ROLES AND LAWFULNESS OF PROCESSING

Who is the data controller in the context of secondary data use?

Compatibility of secondary data use

Legal bases (legal obligation, public interest, legitimate interest, consent)

Post-Authorisation Safety Studies (PASS) or Post-Authorisation Efficacy Studies (PAES)

Studies performed by medicines regulators





RIGHTS OF DATA SUBJECTS

Impact of different legal bases



Information to be provided to data subjects - exceptions

Request to access or a copy of personal data

Request to rectify or complete personal data

Restriction of personal data processing, Right to object

Withdrawal of consent



Drafting status of the Q&As

Phase 1 Drafting of Questions & Answers (Q&As)

- Initial key topics discussed with stakeholders
- Operational scenarios (PAES, PASS, regulators)

Phase 1 Draft Q&As - Informal Consultation

- EC DG SANTE completed
- EC DG JUST ongoing
- European Data Protection Supervisor (EDPS) ongoing

Targeted Stakeholder Consultation

- Based on Discussion Papers (May to July) completed
- Consolidation of feedback received completed

Next Steps

Phase 2 Drafting of Q&As

- Analysis of input received in Targeted Stakeholder Consultation
- Review of comments from EC and EDPS in the informal consultation
- » Update of Phase 1 draft Q&As based on the above

Targeted Consultation of Phase 2 draft Q&As

- EMA Stakeholder representatives » update of draft Q&As
- EMA Scientific Committees » update of draft Q&As

Formal consultation of draft final Q&As

• Consultation with EC (DG SANTE & JUST) and EDPS

Publication of final Q&As



Any questions?



Further information

Orsolya.Eotvos@ema.europa.eu; Sabine.Brosch@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

